Literature DB >> 10355390

Coronary artery bypass grafting with an expanded polytetrafluoroethylene graft.

M Weyand1, S Kerber, C Schmid, N Rolf, H H Scheld.   

Abstract

BACKGROUND: We report our experience with the Perma-Flow aortocoronary-right heart graft in 15 patients in whom autologous conduits were not available.
METHODS: Fifteen patients received 39 coronary anastomoses--10 to left anterior descending coronary artery branches, 15 to circumflex coronary artery branches, and 14 to branches of the right coronary artery. Early angiography was done in 11 patients.
RESULTS: One patient died on postoperative day 17 of multiorgan failure. The graft was patent at postmortem examination. Of 30 coronary anastomoses at risk, 24 were patent. Three connections to the left anterior descending system were occluded in patients with an additional internal mammary artery graft to the same coronary system, and three connections to the circumflex system were occluded in patients with a history of major posterior infarction. Three of five distal anastomoses to the right atrial appendage were occluded, whereas all six connections to the superior vena cava were patent. None of the patients had shown recurrent angina at a mean follow-up of 10.9 months (range, 2-39 months).
CONCLUSIONS: The synthetic Perma-Flow coronary graft appears to be a safe alternative in patients in whom arterial or venous conduits are not available. Competitive flow may lead to anastomotic occlusions. The appropriate site for the distal arteriovenous fistula seems to be the superior vena cava.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10355390     DOI: 10.1016/s0003-4975(99)00168-x

Source DB:  PubMed          Journal:  Ann Thorac Surg        ISSN: 0003-4975            Impact factor:   4.330


  1 in total

1.  Six years of clinical follow-up with endothelial cell-seeded small-diameter vascular grafts during coronary bypass surgery.

Authors:  Pascal M Dohmen; Axel Pruss; Christina Koch; Adrian C Borges; Wolfgang Konertz
Journal:  J Tissue Eng       Date:  2013-09-03       Impact factor: 7.813

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.